Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells.

The bcr1- and bcr3- promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) are the two major fusion proteins expressed in acute promyelocytic leukemia (APL) patients. These proteins, which are present in different lengths of PML (amino acids 1-552 and 1-394, respectively), contain most of the functional domains of PML and RAR alpha, bind all-trans-retinoic acid (t-RA), and act as t-RA-dependent transcription factors. T-RA is an effective inducer of clinical remission only in patients carrying the t(15;17) and expressing the PML/RAR alpha products. However, in APL patients achieving complete remission with t-RA therapy the bcr3-PML/RAR alpha product has been found associated with a poorer prognosis than bcr1-PML/RAR alpha. In the present study we have investigated the structural and functional properties of the bcr3-PML/RAR alpha in comparison to the previously characterized bcr1-PML/RAR alpha. In particular, we have measured the binding properties of the two endogenous ligands t-RA and 9-cis-RA to both of these isoforms. T-RA binding analysis of nuclear and cytosolic extracts prepared from bcr3-PML/RAR alpha APL patients and from bcr3-PML/RAR alpha COS-1 transfected cells indicates that this protein is present only as high-molecular-weight nuclear complexes. Using saturation binding assays and Scatchard analyses we found that t-RA binds with slightly less affinity to the bcr3-PML/RAR alpha receptor than to bcr1-PML/RAR alpha or RAR alpha (Kd = 0.4 nmol/L, 0.13 nmol/L or 0.09 nmol/L, respectively). Moreover, two different high-affinity 9-cis-RA binding sites (Kd = 0.45 and 0.075 nmol/L) were detectable in the bcr3-PML/RAR alpha product but not in the bcr1-PML/RAR alpha product (Kd = 0.77 nmol/L). By competition binding experiments we showed that 9-cis-RA binds with higher specificity to the bcr3-PML/RAR alpha isoform than to the bcr1-PML/RAR alpha or RAR alpha. Consistent with these data, the binding of 9-cis-RA to the bcr3-PML/RAR alpha product resulted in increased transcriptional activation of the RA-responsive element (RARE) TRE, but not of the betaRARE, in transiently transfected COS-1 cells. These results provide evidence indicating that preferential retinoid binding to the different PML/RAR alpha products can be measured.

[1]  F. Mandelli,et al.  AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.

[2]  G. Avvisati,et al.  Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. , 1996, Blood.

[3]  S. Corey,et al.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.

[4]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[5]  J. Grippo,et al.  Mutagenesis of the Ligand Binding Domain of the Human Retinoic Acid Receptor α Identifies Critical Residues for 9-cis-Retinoic Acid Binding (*) , 1995, The Journal of Biological Chemistry.

[6]  T. Naoe,et al.  Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). , 1995, Leukemia.

[7]  J. Bennett,et al.  Characterization of acute promyelocytic leukemia cases with PML-RAR alpha break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. , 1995, Blood.

[8]  H. Dombret,et al.  All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. , 1995, Blood.

[9]  A. Zelenetz,et al.  Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). , 1995, Blood.

[10]  P. Maslak,et al.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. , 1994, Blood.

[11]  P. Abarzúa,et al.  Distinct binding determinants for 9-cis retinoic acid are located within AF-2 of retinoic acid receptor alpha , 1994, Molecular and cellular biology.

[12]  A. Zelent,et al.  PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Pike,et al.  Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. , 1993, The Journal of biological chemistry.

[14]  S. Waxman,et al.  Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. , 1993, Blood.

[15]  R. Warrell,et al.  Acute promyelocytic leukemia. , 1993, The New England journal of medicine.

[16]  A. Zelent,et al.  Fusion between a novel Krüppel‐like zinc finger gene and the retinoic acid receptor‐alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. , 1993, The EMBO journal.

[17]  E. Estey,et al.  Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. , 1992, Blood.

[18]  P G Pelicci,et al.  Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. , 1992, Cancer research.

[19]  E. Dmitrovsky,et al.  Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Lo Coco,et al.  Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. , 1992, The EMBO journal.

[21]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[22]  R. Evans,et al.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. , 1992, Genes & development.

[23]  P. Chambon,et al.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.

[24]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[25]  J. Grippo,et al.  9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.

[26]  P. Freemont,et al.  Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. , 1991, Science.

[27]  P. Chambon,et al.  Retinoic acid receptor gamma: specific immunodetection and phosphorylation , 1991, The Journal of cell biology.

[28]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[29]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[30]  P. Pelicci,et al.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. , 1991, Oncogene.

[31]  F. Lo Coco,et al.  RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. , 1991, Blood.

[32]  E. Dmitrovsky,et al.  Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. , 1990, Journal of the National Cancer Institute.

[33]  P. Pandolfi,et al.  Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias , 1990, The Journal of experimental medicine.

[34]  George,et al.  Expression of nuclear retinoic acid receptors in wild-type and mutant embryonal carcinoma PCC4.aza1R cells. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[35]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[36]  D. Metzger,et al.  The lack of transcriptional activation of the v-erbA oncogene is in part due to a mutation present in the DNA binding domain of the protein. , 1990, Nucleic acids research.

[37]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[38]  H. Stunnenberg,et al.  Identification of a retinoic acid responsive element in the retinoic acid receptor & beta;gene , 1990, Nature.

[39]  J. Grippo,et al.  Identification and characterization of nuclear retinoic acid-binding activity in human myeloblastic leukemia HL-60 cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Chambon,et al.  A third human retinoic acid receptor, hRAR-gamma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Chambon,et al.  Identification of a second human retinoic acid receptor , 1988, Nature.

[42]  R. Evans,et al.  Identification of a new class of steroid hormone receptors , 1988, Nature.

[43]  Pierre Chambon,et al.  A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.

[44]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[45]  R. Schwartz,et al.  Cloning and sequencing of a deoxyribonucleic acid copy of glyceraldehyde-3-phosphate dehydrogenase messenger ribonucleic acid isolated from chicken muscle. , 1983, Biochemistry.

[46]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[47]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[48]  P Chambon,et al.  Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  西村 修一.  Reverse transcription-polymerase chain reaction amplification等を用いた東京地区での糞便からのヒトロタウイルス検出および血清型の研究 , 1993 .

[50]  V. Giguère.  Application of the firefly luciferase reporter gene. , 1991, Methods in molecular biology.